Sleep Disorders

CBT-I treatment was found to provide an overall benefit in preventing incident and recurrent major depression in the patient population, highlighting the need for community-level screening for insomnia.

Here's what is coming soon to NeurologyLive®.

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center provided thoughts on the need to improve awareness of sleep disorders and identifying those who may be eligible for treatment, including pediatric patients. [WATCH TIME: 2 minutes]

Karl Doghramji, MD, the medical director of the Jefferson Sleep Disorders Center at the Vickie and Jack Farber Institute for Neuroscience of Jefferson Health, looks ahead to the needs for sleep care heading into 2022.

Neurology News Network for the week ending November 27, 2021.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 26, 2021.

Closing out his discussion on narcolepsy management, Chris Winter, MD, highlights current unmet needs and shares practical advice for community physicians.

Comprehensive insight on the factors that should inform which therapeutic approach, including novel agents such as solriamfetol, should be used to manage narcolepsy.

The medical director of the Jefferson Sleep Disorders Center at the Vickie and Jack Farber Institute for Neuroscience of Jefferson Health offered his insight into the current state of care for sleep and the progress made this year.

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center provided knowledge on how the presence of other comorbid sleep disorders affects patients with insomnia. [WATCH TIME: 2 minutes]

Here's what is coming soon to NeurologyLive®.

Although not associated with diagnosis, investigators did conclude that substantial/very severe impact of headache attacks and anxiety were correlated with presence of insomnia.

Both fatigue and sleep quality were identified as potential risk factors linking sleep duration and self-rated health.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 19, 2021.

Expert neurologist and sleep specialist Chris Winter, MD, discusses the FDA approval of pitolisant for patients with narcolepsy and excessive daytime sleepiness in the context of his own experience with this novel agent.

Insight on the proper evaluation of excessive daytime sleepiness in patients with narcolepsy, as well as agents that have been used to manage this condition.

Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Karl Doghramji, MD, FAASM, DFAPA.

Contrary to previous expectations, 30 minutes of social media before bedtime did not significantly increase arousal or disturb sleep for study participants.

Patients with REM sleep percentage less than 15% were associated with poorer horizontal optokinetic nystagmus grades and more severe illness.

Here's what is coming soon to NeurologyLive.

Having previously served as head of the organization during the Obama administration, Califf will replace current Acting Commissioner Janet Woodcock, MD.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 12, 2021.

Chris Winter, MD, reflects on the challenges in reaching a differential diagnosis of narcolepsy given the number of diseases with similar presentations.

An expert shares broad perspective on narcolepsy, discussing its causes, differences between types 1 and 2, and symptoms that may occur in patients.

Twelve months after subthalamic deep brain stimulation, patients with and without RBD had MDS-UPDRS IV score decrease, MDS-UPDRS III MedOff decrease, and total LEDD decrease, with no between group difference.